CA2724842A1 - Imidazo[1,2-a]pyridine compounds - Google Patents

Imidazo[1,2-a]pyridine compounds Download PDF

Info

Publication number
CA2724842A1
CA2724842A1 CA2724842A CA2724842A CA2724842A1 CA 2724842 A1 CA2724842 A1 CA 2724842A1 CA 2724842 A CA2724842 A CA 2724842A CA 2724842 A CA2724842 A CA 2724842A CA 2724842 A1 CA2724842 A1 CA 2724842A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
methyl
compound
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2724842A
Other languages
English (en)
French (fr)
Inventor
Qun Kevin Fang
Frank Xinhe Wu
Paul T. Grover
Seth C. Hopkins
Una Campbell
Milan Chytil
Kerry L. Spear
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of CA2724842A1 publication Critical patent/CA2724842A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2724842A 2008-05-19 2009-05-19 Imidazo[1,2-a]pyridine compounds Abandoned CA2724842A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5443208P 2008-05-19 2008-05-19
US5443708P 2008-05-19 2008-05-19
US61/054,437 2008-05-19
US61/054,432 2008-05-19
PCT/US2009/044525 WO2009143156A2 (en) 2008-05-19 2009-05-19 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS

Publications (1)

Publication Number Publication Date
CA2724842A1 true CA2724842A1 (en) 2009-11-26

Family

ID=41031732

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2724842A Abandoned CA2724842A1 (en) 2008-05-19 2009-05-19 Imidazo[1,2-a]pyridine compounds

Country Status (6)

Country Link
US (2) US8497278B2 (enExample)
EP (1) EP2300470A2 (enExample)
JP (2) JP5774982B2 (enExample)
AU (1) AU2009249186B2 (enExample)
CA (1) CA2724842A1 (enExample)
WO (1) WO2009143156A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2213672A4 (en) * 2007-10-24 2012-05-02 Nihon Mediphysics Co Ltd NEW CONNECTION WITH AFFINITY TO AMYLOID
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
CN110483499A (zh) 2009-11-05 2019-11-22 圣母大学 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CA2800618C (en) * 2010-05-26 2018-08-28 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US20140221354A1 (en) * 2011-03-31 2014-08-07 Emblem Technology Transfer Gmbh IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
MX2014014308A (es) * 2012-05-30 2015-02-12 Hoffmann La Roche Pirrolidino heterociclos.
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
EP2869822B1 (en) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Inhibitors of phosphodiesterase 10 enzyme
WO2014187922A1 (en) 2013-05-24 2014-11-27 Iomet Pharma Ltd. Slc2a transporter inhibitors
US10919888B2 (en) 2015-09-17 2021-02-16 University Of Notre Dame Du Lac Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
DK3153506T3 (en) * 2015-10-07 2018-03-26 Sanko Tekstil Isletmeleri San Ve Tic As ISOXAZOLES, PROCEDURE FOR THEIR PREPARATION AND APPLICATIONS THEREOF
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
MX2018007040A (es) 2015-12-10 2018-08-15 Bayer Pharma AG Derivados de 2-fenil-3-(piperazinometil) imidazo[1,2-a] piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios relacionados con el sueño.
CN108699084A (zh) 2015-12-10 2018-10-23 拜耳制药股份公司 取代全氢吡咯并[3,4-c]吡咯衍生物及其用途
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
MY199705A (en) 2015-12-22 2023-11-20 Incyte Corp Heterocyclic compounds as immunomodulators
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102685249B1 (ko) 2016-06-20 2024-07-17 인사이트 코포레이션 면역조절제로서의 복소환식 화합물
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
JOP20190005A1 (ar) * 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
CN106279123B (zh) * 2016-08-15 2018-09-04 郑州大学 3-(苯磺酰甲基)咪唑并杂环类化合物及其合成方法
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
EA039175B1 (ru) * 2016-12-14 2021-12-14 Байер Акциенгезельшафт Замещенные диазагетеробициклические соединения, способ их получения и их применение
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
PE20191532A1 (es) 2016-12-22 2019-10-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119224A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
CN107163039A (zh) * 2017-05-11 2017-09-15 浙江工业大学 一种6‑甲基‑2‑对甲苯基咪唑并[1,2‑a]吡啶‑3‑甲醛的制备方法
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2018227427A1 (en) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Substituted bridged diazepane derivatives and use thereof
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
MD3790877T2 (ro) 2018-05-11 2023-08-31 Incyte Corp Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1
AU2019286312B2 (en) * 2018-06-13 2023-08-17 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as GABA A alpha5 PAM
CN110964020B (zh) * 2018-09-28 2022-06-14 中国科学院大连化学物理研究所 一种制备3’,4’-二氢螺[吲哚啉-3,2’-吡咯]化合物的方法
AU2019416589B2 (en) * 2018-12-29 2023-04-06 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound intermediate, preparation method therefor and application thereof
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
PE20230407A1 (es) 2019-11-11 2023-03-07 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
CN114380819B (zh) * 2020-10-22 2024-08-23 鲁南制药集团股份有限公司 一种唑吡坦中间体化合物
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備ｐｄ－１／ｐｄ－ｌ１抑制劑以及其鹽及結晶形式之方法
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB991589A (en) * 1963-04-30 1965-05-12 Selvi & C Lab Bioterapico Novel [1,2-ª‡]imidazopyridines and a process for the manufacture thereof
US3489755A (en) * 1966-08-03 1970-01-13 Pfizer & Co C Imidazo (1,2-b) pyridazines
US4242513A (en) * 1979-03-05 1980-12-30 Appleton Papers Inc. Lactone compounds containing a heterocyclic radical
GB8305245D0 (en) * 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
FR2568880B1 (fr) * 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
ES2032455T3 (es) * 1986-01-22 1993-02-16 Synthelabo Procedimiento para preparar derivados de 3-acilaminometil-imidazo (-1,2-a)piridinas.
WO1989001333A1 (en) * 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
IN179789B (enExample) * 1992-02-10 1997-12-06 Council Scient Ind Res
FR2714907B1 (fr) * 1994-01-07 1996-03-29 Union Pharma Scient Appl Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant.
JPH09176165A (ja) * 1995-12-25 1997-07-08 Nippon Nohyaku Co Ltd イミダゾ［１，２−ａ］ピリジン誘導体、その製法およびその用途
AU2001270297A1 (en) * 2000-06-30 2002-01-14 Neurogen Corporation 2-phenylimidazo(1,2-a)pyridine derivatives: a new class of gaba brain receptor ligands
DE10040016A1 (de) * 2000-08-16 2002-02-28 Boehringer Ingelheim Pharma Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US6514969B2 (en) * 2000-08-16 2003-02-04 Boehringer Ingelheim Pharma Kg β-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions
SE0100567D0 (sv) * 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
US7148353B2 (en) * 2003-10-28 2006-12-12 Sepracor Inc. Imidazo[1,2-a] pyridine anxiolytics
EP1713784A1 (en) 2004-02-12 2006-10-25 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
CN101065377B (zh) 2004-11-11 2011-07-27 菲尔若国际公司 咪唑并[1,2-a]吡啶化合物、组合物、与其有关的应用和方法
US7666880B2 (en) * 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
MX2007011710A (es) * 2005-03-21 2007-11-20 S Bio Pte Ltd Derivados de imidazo[1,2-a]piridina, preparacion y aplicaciones farmaceuticas.
JP2008542323A (ja) 2005-06-01 2008-11-27 ユセベ ファルマ ソシエテ アノニム ２−オキソ−１−ピロリジン誘導体、その製造方法及びその使用
EP1909910A1 (en) * 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
EP1959959B1 (en) * 2005-12-06 2013-04-10 Merck Sharp & Dohme Corp. Morpholine carboxamide prokineticin receptor antagonists
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
AU2007288124B2 (en) * 2006-08-24 2013-04-04 Australian Nuclear Science & Technology Organisation Fluorinated ligands for targeting peripheral benzodiazepine receptors
MY146474A (en) * 2006-11-06 2012-08-15 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP1974729A1 (en) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms

Also Published As

Publication number Publication date
WO2009143156A2 (en) 2009-11-26
JP5774982B2 (ja) 2015-09-09
EP2300470A2 (en) 2011-03-30
US20110166146A1 (en) 2011-07-07
US20130289013A1 (en) 2013-10-31
WO2009143156A3 (en) 2010-01-14
AU2009249186B2 (en) 2014-05-22
AU2009249186A1 (en) 2009-11-26
US8497278B2 (en) 2013-07-30
JP6211556B2 (ja) 2017-10-11
JP2015180633A (ja) 2015-10-15
JP2011523945A (ja) 2011-08-25

Similar Documents

Publication Publication Date Title
AU2009249186B2 (en) Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators
AU2017348826B2 (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
CA2798634C (en) Pyridone and aza-pyridone compounds and methods of use
CA2880251C (en) Novel heteroaryl and heterocycle compounds, composition and methods thereof
AU2011258436B2 (en) Soluble guanylate cyclase activators
CA2809836C (en) Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase
JP5808869B2 (ja) 二環式ピペラジン化合物
AU2012314518B2 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
JP5766820B2 (ja) Ｐｉ３キナーゼ阻害剤としての複素環化合物
KR101585753B1 (ko) 브루톤 티로신 키나아제의 억제제
CA3121408A1 (en) Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof
US12565490B2 (en) Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease
US11753381B2 (en) Inhibitors of receptor interacting protein kinase I for the treatment of disease
AU2013334236A1 (en) Heteroaryl inhibitors of PDE4
US20040092533A1 (en) Imidazo-pyrimidine derivatives as ligands for gaba receptors
AU2014324595A1 (en) Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
AU2008254588A1 (en) Heterocyclic kinase modulators
CA3077134A1 (en) Pde9 inhibitor and use thereof
WO2017046737A1 (en) 1-phenylpyrrolidin-2-one derivatives as perk inhibitors
WO2023227946A1 (en) Tyk2 inhibitors and uses thereof
TW202313035A (zh) Ｊａｋ２抑制劑及其使用方法
JP2017526685A (ja) 置換縮環ピリミジンおよびその使用
CA2487948A1 (en) Azole methylidene cyanide derivatives and their use as protein kinase modulators
CN118930527A (zh) 酰胺类衍生物调节剂、其制备方法和应用
TW202517633A (zh) 作為選擇性細胞毒性劑之四氫喹唑啉衍生物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140220

FZDE Dead

Effective date: 20200831